Title : [State-of-the-art management of CML in 2015 and future prospects].

Pub. Date : 2015 Oct

PMID : 26458439






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Thus, a third-generation ABL TKI, ponatinib, was developed to inhibit all mutated BCR-ABL and showed clinical efficacy in CML cells harboring T315I. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 Thus, a third-generation ABL TKI, ponatinib, was developed to inhibit all mutated BCR-ABL and showed clinical efficacy in CML cells harboring T315I. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens